Novel Treatment of Inflammatory Bowel Disease Informed by Science and Patient Choice: Prognostic Factors and Treatment Options in Aggressive Disease
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, April 2, 2016
Note: Credit Is No Longer Available
|Russell D. Cohen, MD, FACG, AGAF (Moderator)
Professor of Medicine, Pritzker School of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
University of Chicago Medicine
|Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterololgy
University Of Pennsylvania
|Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Digestive Disease and Surgery
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Inflammatory bowel disease (IBD), which consists of Crohn’s disease and ulcerative colitis, is a chronic inflammatory disease of the gut that develops because of an excessive immune response to the normal gut flora in a genetically susceptible host.1 Current therapies for IBD have not, as yet, been able to prevent the need for surgical intervention in more than 50% of patients with IBD. Education for clinicians who manage patients with moderate-to-severe IBD about the immunopathophysiology of IBD and the latest available options to individualize IBD treatment can reduce the use of corticosteroids and need for hospitalizations or surgery, resulting in improved quality of life for these patients.
On March 11, 2015, a CME Outfitters Live and On Demand featured a discussion of the evolving science of IBD to inform and improve treatment selection focused on clinical response, clinical remission, and mucosal healing associated with positive outcomes. To meet the learning preferences of busy clinicians, the activity has been divided into three short modules.
Module 1: Prognostic Factors and Treatment Options in Aggressive Disease
Module 2: Identifying Primary vs. Secondary Non-Response to Treatment Click here to access this activity
Module 3: Achieving Remission and Mucosal Healing Through Maintenance Treatment Click here to access this activity
Each module is certified for .5 AMA PRA Category 1 Credit™. We encourage participants to complete all three modules to optimize the learning experience and to gain valuable insights for treating their patients with inflammatory bowel disease.
- Festen EA, Weersma RK. How will insights from genetics translate to clinical practice in inflammatory bowel disease? Best Pract Res Clin Gastroenterol. 2014;28(3):387-397. PMID: 24913379.
At the end of this CE activity, participants should be able to:
- Define the mechanism of disease of inflammatory bowel disease (IBD) and the role of novel agents in treatment choices.
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region.
Gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other health care professionals who manage and counsel patients with IBD.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-15-012-H01-P
Activity Type: knowledge-based
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Cohen has disclosed that he has received research grants from Janssen Research & Development, LLC (Johnson & Johnson / Centocor). He serves as a consultant to AbbVie Inc.; Celgene Corporation; Entera Health, Inc.; Hospira, Inc.; Janssen Research & Development, LLC (Johnson & Johnson / Centocor); Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Sandoz Biopharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the speakers bureau of AbbVie Inc.; Entera Health, Inc.; Salix Pharmaceuticals, Inc.; and Shire PLC.
Dr. Lichtenstein has disclosed that he has received research grants from Ferring Pharmaceuticals; Janssen Biotech, Inc./Centocor Ortho Biotech, Inc.; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Shire; UCB, Inc.; and Warner Chilcotte. He serves as a consultant for AbbVie Inc.; Actavis; Alaven Pharmaceutical LLC; Ferring Pharmaceuticals; Hospira; Janssen Biotech, Inc./Centocor Ortho Biotech, Inc.; Luitpold Pharmaceuticals, Inc./American Regent, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Schering-Plough Corporation; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc.; Warner Chilcotte. He has received other financial or material support as Editor, Clinical Advances in Gastroenterology; Editor, Gastroenterology & Hepatology; Ironwood (CME program); Luitpold Pharmaceuticals/American Regent, Inc. (CME); SLACK, Inc. (Book royalty)
Dr. Reguerio has disclosed that he serves as a consultant to AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Frances C. Daniel, MPH (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures have been obtained from CME Outfitters staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Takeda Pharmaceuticals International, Inc., U.S. Region do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).